← Browse all categoriesExplore by study typeExpanded Access clinical trials
Expanded Access lung cancer studies.
4current U.S. studies in this category
Current public records
Studies to explore
Categories organize the public record. They do not determine whether someone is eligible.
Available · Not applicable · NCT07783009The purpose of this expanded access program (EAP) is to provide early access to divarasib to participants with KRAS G12C-positive (KRAS G12C+) advanced or metastatic non-small cell lung cancer (NSCLC), prior to divarasib becoming commercially available in the United States.
Non-small cell lung cancer (NSCLC)KRASMetastatic or stage IVNot applicableAfter prior treatment
No Longer Available · Not applicable · NCT07535359The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to I-DXd for eligible patients with extensive-stage small cell lung cancer (ES-SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen), and for eligible patients who have no suitable treatment options and are not able to enter a clinical study.
Small cell lung cancer (SCLC)Not applicable
Available · Not applicable · NCT06834074The Expanded Access Program will provide an alternate mechanism for patients, who lack satisfactory therapeutic alternatives and cannot participate in a neladalkib clinical trial, to access investigational neladalkib.
Non-small cell lung cancer (NSCLC)ALKNot applicable
No Longer Available · Not applicable · NCT04667234The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.
Non-small cell lung cancer (NSCLC)KRASEarly-stage or resectableLocally advancedMetastatic or stage IV
We use structured ClinicalTrials.gov fields when available and conservative exact-term rules for details such as biomarkers and disease setting. Every study page links to the original record, and only the study team can determine eligibility.
Read the methodology →